Shanghai Bao at nearly 4-week high on China regulator nod to new product
08/04/2026 08:14
** Shanghai Bao Pharmaceuticals 2659.HK climbs 4.4% to HK$107.3, highest since March 13 ** Stock set to rise for fifth straight session ** China-based pharma products researcher and developer's product, Human Hyaluronidase for Injection, with project code KJ017, approved for marketing by China's National Medical Products Administration ** KJ017 is highly glycosylated recombinant human hyaluronidase used as adjuvant to subcutaneous infusion, including sodium chloride injection, sodium lactate Ringer's injection ** YTD, stock up 36.8% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Shanghai Bao Pharmaceuticals Co
See all newsBrief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves Human Hyaluronidase For Injection For Marketing
Shanghai Bao at nearly 4-week high on China regulator nod to new product
Brief: Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors